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Abstract 
The identification of genes whose mutations lead to genetic disorders, is the most 
direct and efficient method to lInderstand the molecular components of diseases with a 
genetic basis. ln this thesis, an attempt is made at lInraveling the mysterious nature of the 
genetic architecture of autism by comparing the traditional polygenic model for the 
genetics of autism with a model based on de novo mutations in multiple genes that is 
largely unaccepted by the scientific community, followed by a scientific write up of two 
experiments. 
Under a polygenic pretense, a transmission disequilibrium test (TOT) was performed 
on 185 trios. Twenty six SNPs spanning 820Kb of the GABAA receptor subunit cluster at 
15q 12 were selected based on minor allele frequency >0.05, spacing, and coverage. This 
led to the identification of three SNP's in transmission disequilibrium: rs6606905, 
rs2078439, as weil rs2873027 whose association has already been show'n in previous 
studies. 
Polyalanine trinucleotide repeats are under increasing scrutiny as they have been 
discovered to be involved in an increasing number of genetic disorders. ln this study, 56 
alanine tracts were screened and compared between 192 patients and 192 controls. This led 
to four distinct groups: one group which revealed no variation in cases or control s, one 
group in which fouI' tracts revealed a high degree of polymorphîsm for which no 
identifiable wild type cou Id be discerned, one group whose variants were matched in cases 
and control s, and one group that contained four alanine tracts from ZIC2, TBLXRJ, 
ARlDJA, FOXD3 and POU3F3 whose rare variants were unmatched in a larger number of 
controls and may warrant future functional studies. 
Keywords: genetics of autistic disorder, de novo mutation, polygenic inheritance, 
association study, GABAA receptor subunit, alanine repeats/expansion/contraction 
Résumé 
L'identification de gènes dont les mutations mènent à de troubles génétiques, est la 
méthode la plus directe et efficace de déterminer et comprendre les composants 
moléculaires de ces affections. Cette thèse tente de dénouer la nature mystérieuse de 
l'architecture génétique de l'autisme, en comparant le modèle polygénique traditionnel 
avec un modèle basé sur des mutations de nova dans des gènes multiples, qui n'est pas 
largement accepté dans la communauté scientifique. Par la suite, deux expériences sont 
exécutées, l'une basée sur tin modèle polygénique et l'autre basée sur un modèle de 
mutations de nova. 
Une étude de déséquilibre de transmission a été effectuée sur 185 trios. 
Vingt-six SNPs comprenant 820 Kb de l'agrégat du récepteur sous-unité GABAA à 15q 12 
ont été sélectionnés basées sur leurs fréquences allèles mineures (>0,05) et leur 
espacement. Trois SNPs avec une association significative ont été identifiés: rs6606905, 
rs2078439, ainsi que r52873027 dont l'association a déjà été démontrée dans des études 
précédentes. 
Pour la deuxième expérience, 56 tractus d'alanine ont été examinés et les variants 
ont été comparés entre 192 patients et 192 contrôles. Quatre groupes distincts ont résulté: 
un groupe n'ayant démontré de variation ni dans les cas affectés, ni dans les contrôles, un 
groupe dans lequel quatre tractus ont révélé un degré élevé de polymorphisme pour lequel 
aucun allèle de type sauvage ne pouvait être discerné, un groupe dont la fréquence des 
variants rares était semblable dans les cas affectés et les contrôles, et lin groupe dont les 
membres pourraient mériter de futures études fonctionnelles, comme quatre tractus alanine 
contenus dans ZIC2, TBLXRJ, ARIDJA. FOXD3 et POU3F3 possédaient des variants 
génétiques non-observés dans les contrôles. 
Mots clés: désordre autistique, mutation de nova, héritage polygénique, études 
d'association, récepteur sous-unité GABAA, expansions/contractions des tractus d'alanine 
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1.0 General Introduction 
In 1943, Leo Kanner published a case report describing Il children with 
subtle phenotypic similarities he termed "autistic disturbances of affective 
contact"l. In this report, Kanner compared and contrasted many phenotypic and 
background commonalities among these children taking note of several features, 
many of which have developed into the modem diagnostic guidelines for autism. 
One of Kanner's contemporaries, a pediatrician from Vienna named Hans 
Asperger, described children with similar developmental difficulties one year 
after Kanner, also using the term autistic to describe his patients2 . This may 
initially seem like a startling coincidence, however autism or autistic had been a 
commonly used term in psychology dating back to 1910 to describe human 
behaviour in which the patient is in social withdrawal, a feature used primarily to 
describe a phenotypic symptom of schizophrenia3. The concurrent clinical 
characterization of autism within this short time frame should not be recognized 
as either a sudden outbreak of a new disorder, or that patients modemly diagnosed 
as autistic did not exist prior to this. It simply represented a shifting cultural 
climate in the psychological features that psychiatrists focused on to categorize 
and diagnose human mental disorders. These guidelines have experienced several 
revisions over the years with many more likely to come as continuing research in 
multiple fields will shed light on this mysterious condition and begin to 
homogenize patients currently diagnosed with autism into different clinical 
categories. 
7 
Due to the work of anthropologist Margaret Mead in the early 1900'S4, it 
was a commonly held belief that the human brain and associated personality was 
a blank slate, with little to no contribution from genetic factors5. Therefore, most 
psychiatric conditions had a large bias towards examining the parents of affected 
individu ais to determine the cause of the disorder. When autism was initially 
described, the search began for the environmental component that led to this 
disease. Unfortunately, scientific rigor in the field of psychology was applied 
loosely during this period, therefore weak observations often led to dominating 
theories regarding the cause of autism. Observations of socially reticent mothers 
of autistic children led to the "refrigerator mother" theory of autism, a theory that 
posited that infants that do not get the proper care from the mother will experience 
developmental delays resulting in autism. In 1957, Leon Eisenberg reported that 
often the fathers of autistic children were socially isolated, which led to the idea 
that perhaps the behaviour of both parents cou Id lead to the autistic phenotype in 
their children6. This idea was held as common belief for much of the mid 1900's 
and was not completely abolished until early twin studies in 1977 had definitively 
shown a genetic basis for the disorder7, although the concept likely remained 
embedded within the general public for several years afterwards. 
Autism has become the focus ofmuch more publicity and research as data 
amassed between 1991-1997 resulted in a reported 556% increase in the 
prevalence8, a dramatic increase that sparked public concem. A crisis developed 
in the late 1990s, as several individuals presented anecdotal evidence that pointed 
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to the measles, mumps, rubella (MMR) vaccine as the causal agent behind the 
outbreak. However, there is no epidemiological evidence to suggest that the 
MMR vaccine conf ers any risk to developing the autism phenotype9• Afterwards 
it was suggested that perhaps thimerosal, a mercury containing preservative used 
in vaccines, was associated with autism 10, although recent studies have refuted 
this hypothesis 11, 12. Furthermore, no evidence at this point supports an increased 
incidence of the disease, as studies reporting an increased prevalence did not 
control for changes in diagnostic criteria for autism that took place in 199413, 
Currently, the general term autism has been replaced with autistic 
spectrum disorder (ASD) and is diagnosed in accordance with the classifications 
set forth in the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision 7 (DSM-IV) and the International Classification of 
Diseases, Tenth Revision (ICD-lO) 14, IS. According to these diagnostic manuals, 
ASD is characterized by impairments in three behavioral domains: 1) social 
interaction; 2) language, communication, and imaginative play; and 3) range of 
interests and activities. ASD has been further subdivided into five subtypes 
according to the varying clinical presentations of the above three phenotypic 
characteristics: 1) the prototypical Autistic Disorder (AD) 2) Asperger Syndrome 
(AS), which is generally recognized as a milder form of AD without the 
associated language delay 3) Pervasive Developmental Disorder Not Otherwise 
Specified (PDD-NOS) 4) Childhood Disintegrative Disorder, a rarely diagnosed 
condition where a childhood experiences dramatic regression between two and ten 
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years of age after normal development and 5) Rett Syndrome (RS) a genetic 
disorder of postnatal brain development, caused by a single-gene defect 
predominantly affecting girls. 
This thesis will focus on the disco very of genetic elements that lead to the 
phenotypes in categories 1-3, AD, AS and PDD-NOS. Although psychiatrists 
have developed these diagnostic criteria in an attempt to categorize and 
homogenize patients in a meaningful way, there is no evidence that these 
classifications homogenize patients based on the underlying genetic mutations 
involved. Due to the subtle differences between these categories the profound 
impact of differential diagnosis, as well as differing clinical presentations that 
depend on the age of the child during examination, the same mutation can lead to 
a variable diagnoses on the autistic spectrum. In fact, this has been shown for the 
known genetic mutations that lead to the AD phenotype. In one instance a sibling 
pair discovered to share a single gene defect in the NLGN3 gene, each received a 
different diagnosis; one with AD, the other with AS 16. In another example, a 
large multiplex pedigree with 13 affected individuals shared a fully penetrant 
mutation in NLGN4 with perfect x-linked segregation, which resulted in multiple 
diagnoses including AD, PDD-NOS as well as X-linked mental retardation 
(XLMR)17. Therefore, for the purpose of discovering genes that lead to the 
autistic phenotype, the three clinical categories that are focused on in this thesis 
can be treated as one, and will be referred to as autistic disorder (AD). 
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1.1 Pathology 
Symptoms of AD generally begin to appear between 12-36 months after 
birth. This is usually preceded with no phenotypic symptoms or signs until the age 
of onset, which makes this disorder both mysterious and distressing. However, the 
age of onset reveals the importance of this molecular developmental time period 
of the nervous system, as it coincides with the appearance of spatial and temporal 
transcriptional cascades that lead to remodeling and elaboration of neuronal 
circuitryI8,19. The discovery of genes that lead to the AD phenotype should 
provide insight into this process. To date, neuroscientists have discovered very 
few physical abnormalities in the brains of autistic children, none of which are 
hallmark signatures common to all patients diagnosed with AD. Increased 
hippocampal and amygdala volumes have been reported in sorne children and 
sorne adults with autism20. Furthermore, damage to the amygdala has been 
hypothesized to play a role in the onset of the disorde?l, 22, although this theory 
has received less attention in recent years. Hyperserotonemia has been observed 
in children as weIl as families of children with AD23, 24, which has led to several 
examinations of polymorphisms within the serotonin transporter gene25-28, 
although the se studies have failed to conclusively determine any association with 
AD28. Macrocephaly (head circumference > 95th percentile) is observed in 
approximately 20% of patients with AD29, as weIl as epilepsy in approximately 
30%30,31. 
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1.2 Evidence that genetic factors lead to the AD phenotype 
Familial aggregation studies have shown that the sibling recurrence rate of 
AD is approximately 2-8%, with the most commonly accepted value currently at 
4.5%32,33, whereas the population prevalence is currently estimated at 0.5-0.6%34. 
This information reveals that there is a higher tendency for autism to c1uster in 
families, however does not point exc1usively to a genetic origin, as it does not mIe 
out a shared environment unless combined with data from twin studies. To date, 
three twin studies of AD have been performed, each using small sample sizes 7, 35, 
36. Combining these three studies, the total number of twin pairs is 66, with 36 
monozygotic (MZ) pairs and 30 di-zygotic (DZ) pairs. The average MZ 
concordance rate is 70%, with values ranging from 60-90%, compared with a DZ 
rate of 0%. The observed rate of 0% is a chance finding that likely results from 
the small number of DZ pairs in these studies. This is based on the observance 
that concordant DZ twin pairs do exist, therefore the DZ concordance rate is 
likely c10ser to the sibling recurrence rate of ~4-5%, considering DZ twin pairs 
share the same environment and proportion of genetic content. Although a shared 
environment cannot be eliminated for studies involving sibling recurrence, the 
much higher concordance rate between MZ and DZ twins suggests that genetic 
factors are the dominant factor in the development of the disease. 
Finding the genetic elements that lead to human disease represent a 
powerful "bottom up" approach to understanding human disorders that have a 
genetic component. Insight into the genetic mutations responsible will provide 
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infonnation on the molecular pathology of human disease and also be seamlessly 
integrated into neurological, physiological and clinical data. The discovery of 
these genetic elements that lead to the autistic phenotype is likely to be the most 
direct route towards early detection, as well as assembling a pennanent cure that 
alleviates all associated autistic phenotypes. 
The most important consideration wh en attempting to discover genetic 
factors that lead to disease, is to first understand the inheritance mechanism or 
genetic architecture of the disorder in order to detennine the appropriate gene 
identification strategy. For example, in the case of a genetic condition resulting 
from a simple single-gene mendelian disorder, a family based linkage study can 
be perfonned and combined with other linkage studies to refine the segregating 
chromosomal region containing the mutation. However, it was clear from the 
beginning of the twin studies that AD is not a simple mendelian disorder, as one 
mutation in one gene would result in a MZ concordance rate closer to 100% and 
DZ concordance closer to 50%. The actual MZ and DZ concordance rates have 
led researchers to pursue gene identification strategies based on a polygenic 
model with as many as 2-15 genes interacting to produce the AD phenotype that 
dominates the literature today. However another model based on de nova 
mutations has been largely ignored by the scientific community and will be 
presented and contrasted within this thesis. 
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1.3 The polygenic model, common disease/common variant 
The po1ygenic mode1 for autism posits that multiple functional allelic 
variants are present within the global gene pool that each contribute to the autistic 
phenotype. The exact proportion, distribution, and genes involved within each 
patient will vary under this mode1, producing a large array of phenotypes under 
the autistic spectrum. This model was originally intuitive to the scientific 
community given the data from twin studies: if the MZ concordance is ~90% and 
the DZ concordance/sib1ing recurrence is ~4-5%, it is quite 10gical to assume a 
polygenic model for autism, given that the concordance will be essentially ha1ved 
for each additionallocus involved. For example, if five loci are involved then the 
probability of a twin pair being concordant for autism is MZ=l 00%, DZ= (0.5)5 = 
3.125%, which is very close to the observed value. It would also follow that in the 
twin that failed to meet diagnostic threshold there may be a broader spectrum. 
For example, ifthis twin inherited 2/5 of the AD conferring alleles rather than the 
entire suite, he or she may be partially affected. This is also the case as the twin 
studies report that discordant twins often show symptoms of the broader 
phenotype. The intuitive nature of this model for AD has led to countless sib-pair 
linkage and association studies, however these strategies have yet to identify a 
causal genetic variant or mutation that leads to the AD phenotype. 
1.4 The multi-locus monogenic model dominated by low transmission of de 
novo mutations (DNM model) 
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The limitations of current sequencing technologies have made it difficult 
to accurately assess the rate and role of new mutations in complex genetic 
disorders. Although obtaining precise, multi-generational genome-wide sequence 
information is not currently plausible, it is still possible to examine the empirical 
data that are directly influenced by the underlying genetic architecture, to deduce 
the potential contributions de nova mutations may provide to the overall 
proportion of diagnosed AD cases. 
The DNM model posits that the genetic basis of AD can be explained by 
monogenic de nova mutations in numerous genes across several molecular 
pathways in the absence of other predisposing variants. These de nova mutations 
would be highly penetrant, and rarely transmitted to offspring due to the strong 
negative selection against the phenotype. It has been well established that large 
scale de nova chromosomal anomalies occur frequently in patients with AD, 
explaining approximately 5-10% of cases37, 38, inc1uding a recent report showing a 
strong association with de nova copy number variation (CNV)39. It is also 
believed that techniques providing higher resolution of CNV will likely identify 
smaller de nova copy number variants responsible for an even higher overall 
proportion of AD cases40 . The remaining unidentified cases are currently 
believed to result from polygenic inheritance with multiple common and rare 
allelic variants contributing to the phenotype. However, little consideration has 
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been given to the possibility of even higher resolution de nova mutations (point 
mutations, expansions/contractions of repeated genomic segments of DNA, de 
nova epigenetic mutations). 
To date, the mutations that have been discovered in individuals displaying 
the AD phenotype have arisen de nova, and are primari1y involved in synaptic 
bl ' hm' dl" 16 17 40 41 M . h 1 b esta lS ent, mamtenance an p astI cIty , , , . utatlOns ave a so een 
described in transcription factors expressed in the fetal brain in the case of ARX42 , 
RNA binding translational repression in the case of FMRl (the gene responsible 
for fragile-X syndrome43,44), transcriptional regulation in the case of MECP2 and 
Rett syndrome, as weIl as the tumour suppressor genes TSCl and TSC244, 45. 
These represent dysfunction in a vast array of molecular pathways and functional 
structures, aIl leading to the same general phenotype, implicating thousands of 
potential candidate genes. For example, using conservative numbers, there are 
approximate1y 5,000 genes expressed at the synapse that contribute to synaptic 
function, countless more are brain-expressed embryonic transcription factors, 
translational repressors and tumour suppressors. Certainly, mutations in aIl of 
these candidate genes and their downstream targets are not likely to produce the 
AD phenotype, however there is clearly a potential for the same phenotype to 
arise as a result of monogenic mutations in any one of several hundred genes. 
Although not aIl amino acid substitutions will have a functional effect, a 
significant fraction will lead to disease. It has been estimated that in every zygote, 
there are approximately 1-3 new deleterious mutations that lead to an altered 
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ammo acid per genome, this is on average 1 new mutation per 10,000 
genes/zygote46,47,48. Therefore, for a disease such as AD that may result from 
dysfunction in any one of hundreds of different genes, new mutations may be 
responsible for a significant fraction of cases. Examining conditions for which 
genes have previous1y been identified, it is evident that new mutations are 
common. For example, 1/6,000 live births harbor a novel mutation causing 
neurofibromatosis type 1 (NF1)49,5o. The frequency of new point mutations in 
Duchenne Muscular Dystrophy is similar: III 0,500 live births51 . These are large 
genes allowing for a high mutation rate, however their total genomic size is a 
small fraction compared to the genomic size of the hundreds of potential genes 
that may all produce the same general AD phenotype. Examining a smaller gene, 
Rett syndrome is a c1inically characterized phenotype within the ASD spectrum, 
and results from mutations in the small MECP2 gene involved in transcriptional 
regulation. The incidence of Rett syndrome is one in 10,000-15,000 females, and 
99-99.5% of all cases are sporadic resulting from new mutations; this represents a 
new mutation rate of one in 5,000-7,500 live births for this small gene of 498 
amino acids52,53,54. 
It has been estimated that the mutation rate of a repetitive stretch of 
genomic DNA is approximately 100,000 fold more frequent than common point 
mutations55. These stretches can code for poly-amino acid tracts, which are found 
in hundreds of genes throughout the genome, or for regulatory elements such as 
FMR1. For example, alanine tract expansions in the ARX gene, a transcription 
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factor expressed in the fetal brain, produces a broad spectrum of disorders 
inc1uding epilepsy, mental retardation and the AD phenotype42, 56. In the case of 
FMR1, an expansion of the repeat within the upstream regulatory region leads to 
hypermethylation and silenced gene expression57 . Given the ubiquitous dispersal 
of repetitive stretches of DNA located throughout the genome within coding 
regions or regulatory genetic elements, de nova expansions or contractions of 
these repetitive elements cou Id account for an appreciable fraction of AD cases as 
weIl. 
The male:female ratio of mutation rate is estimated at about 4-6:1, 
presumably due to a higher number of germ-cell divisions with age in males. 
Therefore, the DNM model would predict that de nova mutations arising in the 
germ line would more frequently come from males, particularly with advancing 
patemal age58 . The higherpatemal origin of de nova mutations has been shown for 
many diseases, inc1uding Apert syndrome59, Crouzon syndroméO, NF1 61 , 
Alexander disease62 and Rett syndrome63 ,64. Sorne authors have even predicted a 
high incidence ofmale-derived novel mutations in human mental disorders65,66. A 
recent review has actually highlighted the association between advancing patemal 
age and autism 67, just as the DNM model predicts. 
Considering the complete penetrance of the previously described 
mutations discovered in patients diagnosed with c1assic forms of AD16, 17,41, it is 
likely that these mutations produced phenotypic effects without the presence of 
other genomic variants. Taken together, these examples show that de nova mutations 
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can occur with a high enough frequency to explain the relatively high incidence of AD, as 
weIl as act dominantly to do so. Mutations in known genes for AD currently explain a 
small fraction of cases. Under the DNM model, over time, more monogenic mutations will 
be discovered in different genes, each contributing a small portion of the overall disease 
incidence. Eventually, a rare causal monogenic mutation could be identified for the 
majority of patients diagnosed with AD. 
2.0 The strength of each model at predicting and explaining 
factors influenced by underlying genetic architecture 
As previously mentioned, determining which model more accurately explains aIl 
of the data influenced by the underlying genetic architecture is extremely important as it 
will have a profound influence on the type of strategy employed to discover these genetic 
elements. Therefore, before beginning it is necessary to examine aIl of the recent literature 
relevant to the field of genetics and examine the power each model has at explaining the 
data. 
2.1 Twin studies and sibling recurrence 
As mentioned above, the MZ twin concordance rate for AD is 70-90% and 
the DZ concordance is similar to the sibling recurrence rate of 0-10%, with the 
extreme values likely representative of smaller sample sizes7,35,68. Given these 
numbers, there are two possible explanations for the data; a polygenic model 
involving several genes interacting with environmental factors, or the de nova 
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mutations model mentioned above. An example of how the DNM model could 
hypothetically provide the observed sibling recurrence rate is shown in Table 1. 
Table 1 : Hypothetical example of an AD patient cohort that leads to the empirically observed values for 
sibling recurrence. 
Inheritance # Families Recurrence No Recurrence 
Autosomal Dominant 15 3 12 
variable expressivity 
Autosomal Recessive 12 2 10 
X-Linked 18 3 15 
Mutation in 7 3 4 
Imprinted Gene 
de novo in affected 125 0 125 
Total 178 11 166 
Sibling recurrence 11/178 = 6.2% 
The majority of these de nova mutations will occur in the affected 
individuals and not be transmitted; however, they can be transmitted from 
unaffected parents to multiple affected siblings as a result of maternaI 
transmission of mutations on the X chromosome to male offspring16, 17 or of 
gonadal mosaicism40, 41, which wou Id aU result in higher sibling recurrence rates. 
In fact, the transmission pattern of the four genes discovered to be mutated in 
patients with AD (NLGN3, NLGN4, SHANK3, and NRXNl) aU fall within one of 
the above categories. Furthermore, it is also theoreticaUy possible for 
transmission to occur from asymptomatic parents via autosomal recessive 
inheritance patterns, as well as through mutations in imprinted genes although 
specific examples of such are yet to be discovered. 
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Although perfect concordance is not observed between autistic MZ twins, 
this does not necessarily imply that a contribution of environmental factors must 
play a role in producing the AD phenotype in the affected twin. With the DNM 
model, discordance would occur as a result of X-linked inactivation69, predicting 
that female MZ twin pairs will be more discordant than males, we are unaware of 
any data reporting separate concordance rates for male or female twin pairs. 
Discordance between MZ twins would also occur from somatic mosaicism 
for a de novo mutation that occurred early in development in only one of the two 
developing zygotes, or autosomal dominance with variable expressivity 
potentially resulting from stochastic events during embryogenesis. 
These novel considerations of the DNM model present implications for 
genetic counseling. Parents of autistic children are often informed that the sibling 
recurrence rate of autism is between 5-10% when planning for their next chi Id. 
The DNM model predicts that the probability of future siblings being affected 
with autism is much higher when a second child is born with AD, as it shows that 
the underlying defect is being transmitted from one of the parents via one of the 
unknown transmission patterns mentioned in Table l (page 19). 
2.2 Wide clinical spectrum associated with AD 
Psychiatrists and psychologists are burdened with the task of collecting 
clinical information and developing diagnostic criteria for brain disorders. When 
examining a transient position on a scale of conti nuit y, su ch as a poorly 
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developing child with global brain dysfunction and a fluctuating vocabulary, it 
becomes difficult to develop clinical categories and thresholds that will apply on 
the genetic level. This is especially true when attempting to account for the 
shifting landscapes of brain development into adolescence and adulthood. 
Therefore, a wide clinical spectrum is present in ASD, where sorne individuals are 
high functioning college students with above average IQs70, sorne can perfonn 
astonishing memory feats and calculations 71, while others are non-verbal with 
severe mental retardation involving self injurl. Co-morbidity with epilepsy is 
estimated at approximately 30%30, 31, while a strict definition of macrocephaly is 
observed in approximately 20% of children diagnosed with AD29. 
This wide variation in clinical presentation is currently explained with 
polygenic inheritance of many common alle1es at multiple loci. These alle1es are 
thought to combine in numerous pennutations to produce a vast array of hannful 
phenotypes, the logistics ofwhich will be confronted in a later section. 
When accounting for this clinical variation with the DNM model, the wide 
variation in clinical presentation would be explained by new mutations in 
numerous genes that function in multiple molecular pathways producing 
phenotypes on a large spectrum. This spectrum makes it impossible to detennine 
a boundary or threshold that will homogenize patients on the genetic level. 
The clinical difficulty of homogenizing patients is even present in families 
where a single mutation is responsible for the phenotype. The large family 
presented by Laumonnier et. al, displayed several individuals with various clinical 
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a11eles to produce the AD phenotype, or are they more simply a reflection of the 
clinical difficulties surrounding the ability to define AD on a level that is 
consistent with the underlying biological origin? Linkage analysis of this family 
identified a single mutation in NLGN4 segregating in perfect X-linked 
transmission through a11 affected individuals, including obligate carriers with 
100% penetrance17• This seems to indicate that this mutation is acting 
monogenically, and the diagnostic disparities are more likely confounded by 
varying stages of development at diagnosis and clinical heterogeneity rather than 
the presence of additional alleles that produce the AD phenotype. 
Admittedly, the DNM model does not apply to high functioning adults 
leading relatively normal lives. Many individuals are suggested to faU within the 
broad ASD spectrum based on personality characteristics that are held in common 
with some patients diagnosed with AD, such as social difficulties and the inability 
to accept changes in their lifestyle. Although the wanton eye may he able to 
identify parallels on the phenotypic level between a high functioning asocial 
coUege student and an individual with mental retardation that requires constant 
supervision, this does not necessarily mean that there is a connection between 
their conditions on the genetic level. Many of the se high functioning adults 
diagnosed with AD may carry a specific combination of common variants 
shrouded by environmental events that lead to social difficulties, just as any other 
individual may have a mix of common variants and environmental components 
that lead to their own hehavioural quirks. It thus becomes a philosophical question 
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as to whether their behaviour lies within the normal range of human variation. 
This model is only meant to apply to individuals with a clear phenotypic 
developmental delay and mental retardation that progress into adulthood. 
2.3 Failure of linkage and association studies to identify genes involved in AD 
There have been a very large number of association studies perfonned 
with the goal of identifying the common alleles that contribute to the autistic 
phenotype under the pretense of a polygenic model72• None of these have been 
able to identify a single gene or variant with any considerable level of 
consistency. There have also been numerous linkage studies combining multiple 
small families that have produced inconsistent results, with linkage peaks 
spattered across the entire genome72• Although sorne regions have been replicated 
across studies, none of them have ever been replicated consistently in all studies 
involved. The explanation provided for the inadequacy of these studies to produce 
digestible results involves the addition of more and more allelic variants that 
contribute a smaller and smaller portion of the phenotype. The infonnation 
gleaned from combining small families to perfonn linkage studies does in fact tell 
us that multiple loci are involved. Even under a monogenic model, a smal1 
number of genes will produce consistent linkage peaks if the majority of cases 
resulted from low transmission of de novo mutations occurring on different 
haplotypes at a small number ofloci. However, smce consistently replicated 
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linkage peaks have not been observed, multiple loci throughout the genome must 
be involved, wh ether one considers a polygenic model or the DNM model. 
A problem arises wh en one considers the utility of using association 
studies to identify AD genetic variants under both models. When viewed from the 
perspective of a polygenic model, association studies should be the ideal method 
to identify the loci that contribute to the AD phenotype, especially considering the 
recent validation of the technique in other complex traits 73-75. However, it should 
be noted that the genetic variants identified using this technique were represented 
in adult onset disorders, in which little selection occurs against the phenotype. 
Assuming the polygenic model explains the majority of cases, the inability 
to globally replicate association studies must result from either choosing the 
wrong loci to study, or from a high number of loci that only contribute small 
percentages of the phenotyPe which can vary based on the cohort of patients 
involved in the study. The solution to this problem would be to increase power by 
adding more patients to these studies as well as the investigation of many more 
loci in an effort to identify these variants. However, under the DNM model, it is 
evident that association studies will fail to identify these variants, as new 
penetrant mutations that are strongly selected against will never become in 
linkage disequilibrium with any genomic marker. 
The inability of association and small family linkage studies to identify 
genetic variants can always be explained by adding additional contributing loci 
under a polygenic model. The question that must be posed is how much further 
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should this approach be taken before an alternative genetic mechanism IS 
considered? 
2.4 Consistent global prevalence 
Obtaining complete, global disease prevalence data for AD has not been 
accomplished, as diagnostic disparities coupled with little clinical investigation of 
AD in certain regions is difficult. However, to date epidemiological studies have 
failed to conclusively reveal an uneven distribution of AD from any ethnic or 
socioeconomic background34, 76. One of the many perplexing aspects of AD is its 
genetic basis, however an un-even global distribution is not observed. Under a 
polygenic model this could only be reconciled by the existence of allelic variants 
that confer a susceptibility to AD dating back to a common founder population for 
an of humanity, otherwise many pockets of the globe would be void of 
individuals with AD. These variants would have had to be spread globally 
through small human populations as they migrated to various locations around the 
world. Information gleaned from the International Hapmap project has shown that 
a considerable amount of human genetic variation is common between several 
populations around the globe, indicating that a substantial proportion of variants 
date back to a common founder population77 . Therefore, on the surface the 
concept seems plausible. 
In small isolated founder populations, such as those likely found in our 
ancestral environment, the genetic variation is reduced with a concomitant 
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increase in homozygosity at all loci. This would mean that under a polygenic 
model, the allelic variants that produce the AD phenotype must have combined 
more frequently to produce individuals that would be modernly diagnosed as 
autistic. In order for these variants to have remained globally consistent, there 
could not have been any selection acting against them, nor any fixation by genetic 
drift during small population migrations and settlements, otherwise an uneven 
disease distribution would be presently observed. 
Considering the refusaI of female chimpanzees to raise offspring that fail 
to develop a maternaI bond, it is conceivable that there was a high degree of 
selection against the autism phenotype in our evolutionary ancestral environment. 
It has even been proposed that parental selection played a large role in human 
evolution, as raising children would have been difficult and expensive for hunter 
gatherer communities78 . It is noteworthy that the decision to care for and raise an 
autistic chi Id is still difficult for many parents in the recent western cultural 
environment, exemplified by the number of autistic children that are placed in 
psychiatric homes. In our modem environment, autistic individuals frequently 
survive to adulthood, yet strong negative selection still occurs against the 
phenotype evidenced by the low AD reproductive rates79• 
A gene pool is a reflection of successful reproductions between ancestral 
genomes that were composed of allelic variants whose collective actions 
conferred advantages to their historical possessors. The persistence of allelic 
variants under negative selection throughout evolutionary history in all human 
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populations disagrees with evolution at the genetic level and would require an 
explanation. Considering the low transmission of the AD conferring allelic 
variants, it is thus very unlikely that a polygenic model could explain an ev en 
disease distribution around the globe. 
It is possible that particular variants present in the maternaI and paternal 
lineage functioned properly/co-operated well separately in the ancestral gene 
pool, but can not execute the proper function when co-expressed in the same 
genome. For example, a poor fit between a corn mon neurotransmitter variant from 
one population, and a variant present within its receptor in another population 
could result in altered neurotransmission. In fact, this would be predicted in a 
species with many isolated populations where there is a considerable amount of 
genetic variation within populations rather than between populations. However, 
this is not the case with humans, and there is no evidence suggesting that parents 
of mixed ethnie backgrounds are more likely to have autistic children than 
families with homogenous ethnie backgrounds. 
Analyzing this observed feature using the DNM mode 1, an even disease 
distribution is actually predicted, as mutation rates should not be considerably 
different between any specifie global populations. 
2.5 Skewed male to female AD ratio 
It is already commonly understood that males are more prone to 
developing the autistic phenotype than females, by a ratio of ~ 4: 132 . Under a 
28 
polygenic model, it has been suggested that intrinsic differences between male 
and female brains on the psychologicallevel may account for the reasons why one 
sex is more vulnerable to the AD conferring allelic variants80. However, there is 
currently no strong evidence to support this. Furthermore, there has been little 
evidence from the neuroscience field to explain how inherent anatomical 
differences between males and females would predispose one sex to the AD 
phenotype, given the same genetic background and relative proportion of genetic 
variants. 
The DNM model wou Id actually predict an uneven sex ratio between 
males and females. When diploidy arose in our cellular ancestor, it likely 
conferred a selective advantage due to its protective mechanism against de nova 
mutations. The majority of de nova mutations that result in the production of a 
faulty protein will not display a phenotype, as its effects can be masked by the 
expression of the other allele. This is the case with aIl of the autosomes, however, 
in males the hemizygous X chromosome is exposed to the effects of every de 
nova mutation that occur. It would also be predicted that females with only one 
X-chromosome, such as a patient with Tumer's syndrome, would be at an 
increased risk for AD compared to other women, although we are unaware if su ch 
a study has been performed. 
Furthermore, de nova mutations occurrmg on the X chromosome in 
females can be briefly transmitted to produce affected males, unless unfavourable 
X-inactivation produces a phenotype in females. However, it would be rare for the 
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transmission to occur through multiple generations, as the penetrant mutation is 
unlikely to be transmitted from male offspring. 
2.6 Presence of autistic features in first degree relatives 
Many studies have observed that first degree relatives of individuals 
diagnosed with AD can often show sorne of the phenotypic symptoms of autism 
as we1l81 , 82. These studies have been carefully conducted with proper controls 
and are able to consistently achieve statistical significance. 
A polygenic model would explain this in terms of allelic AD variants for 
every autistic trait circulating in the population. The child diagnosed with AD 
would be considered unfortunate to have acquired by chance a higher number of 
these allelic variants, which caused him/her to surpass the threshold in the 
phenotypic triad (social interactions, language/communication and range of 
interests and activities). The existence and transmission ofharmful allelic variants 
through multiple generations has been discussed in a previous section. 
It has also been suggested that the allelic variants predisposing to the 
phenotypic triad are inherited separatell3. However, this poses a perplexing 
question: how do the allelic variants predisposing to the phenotypic triad tend to 
co-occur? The existence ofnumerous tightly linked haplotypes located throughout 
the genome containing c1usters of AD-conferring allelic variants that have 
managed to evade natural selection is unlikely. There could be an unknown 
mechanism that leads to this higher than expected co-segregation, or a synergistic 
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relationship between them. However, mutations in several genes have already 
been discovered whose global brain expression results in global deficits in all 
hr d . . h h 'b' c: h Il l' . 16 17 40 41 h' h t ee omams Wlt out t e contn utlOn lrom ot er a e IC vanants ' , , ,w IC 
questions the necessity of investigating this avenue. 
Under the DNM model, the examples of clearly identifiable, carefuIly 
controlled observation of milder forms of autistic symptoms in first degree 
relatives cou Id result from X-linked inactivation in females, as weIl as autosomal 
dominant inheritance with variable expressivity. X-linked inactivation will 
produce a diverse array of phenotypes in female patients, dependent on the 
location of inactivation of the favorable chromosome. It is easy to imagine the 
implications of this if stochasticity resulted in the inactivation of the unaffected 
chromosome in only a portion of the brain of female carriers. This would 
conceivably result in various phenotypes depending on the function of the gene as 
weIl as the proportion and location of the expression of the mutant copy. 
Autosomal dominant mutations in genes that are involved in embryonic 
development can result in an incredibly diverse array of phenotypes. Mutations in 
the Sonic Hedgehog protein (SHH), for instance, result in holoprosencephaly, a 
condition whose behavioural and cognitive phenotype can be similar to AD. 
Mutations in this gene can result in dramaticaIly different phenotypes, from 
cyclopia in one family member to slight midline abnormalities in the next84. If 
the phenotype of mutant SHH-associated holoprosencephaly were defined on 
narrowed thresholds, there would undoubtedly be pure cases of 
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holoprosencephaly, with siblings showing the broader spectrum of 
holoprosencephalic features. The mechanism that leads to a phenotype with 
variable expressivity at most loci is unknown; it is therefore possible that other 
genetic variants as weIl as environmental factors may influence the AD phenotype 
when such a gene is mutated. 
2.7 Lack of family history in majority of patients diagnosed with AD 
The frequent occurrence of AD with no family history could be explained 
on multiple levels, depending on the particular family in question. In sorne 
families, the fluctuating diagnostic criteria as well as the difficulty of defining AD 
in adults that were not clinically assessed in their infancy, presents clear historical 
difficulties. However, in many families there is no history of mental retardation, 
or any phenotypes that could be confused with AD. 
Under a polygenic model, multiple allelic variants would be assumed to be 
present within the maternaI and paternal lineages that culminate in an offspring 
with no symptoms ever described in distant relatives, the logistics of which have 
been dealt with in a previous section. 
The DNM mode l, on the other hand, would predict that the majority of 
individuals diagnosed as autistic would have no family history because their 
mutation would be an isolated event. If this is the case, offspring of individuals 
with AD would have a much higher frequency of AD. However, no data have 
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been generated or analyzed in this regard since, as previously mentioned, the 
reproductive rate of autistic individuals is very low79. 
2.9 Which model is more consistent with the data? 
The DNM and polygenic models were presented separately as a means to 
show that the DNM model has the power to explain all of the data and 
observations surrounding the AD phenotype, whereas the polygenic model has 
several inconsistencies. However, this does not mean that polygenicity cannot 
play a role in AD. In fact, a polygenic model and the DNM model are not 
mutually exclusive. However, wh en coupled with the DNM model, the proportion 
of cases that will be explained by polygenic inheritance as well as the number of 
interacting variants must be far lower than is currently believed. 
Although ASD represent a continuum on the phenotypic level, this does 
not necessarily imply the presence of a continuum at the genetic level. It is 
possible that numerous monogenic, dis crete genetic mutations can produce a large 
spectrum of inextricable phenotypes. This would make it almost impossible to 
create phenotypic subsets of patients that correspond to the underlying genetic 
mutation without the conceit of hindsight provided after the genetic mutation is 
identified in a particular patient. Evidence has already shown that de nova 
mutations play a role in the onset of AD; the current remaining question IS 
whether a DNM model underlies the majority or aIl of the remaining cases. 
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2.10 Environmental component analyzed with both models 
Several environmental agents have been studied for a potential association 
with AD, including the measles, mumps, rubella (MMR) vaccine, obstetric 
complications85 , intrauterine bleeding, infection, caesarian deliverl6, as well as 
the exposure to hannful substances such as Thalidomide87 . To date, there are no 
environmental agents or exposures that have been consistently replicated and 
definitively proven to lead to the AD phenotype, however examination of the 
DNM and polygenic models for AD can reveal the potential role for an 
environmental source or component. 
Under a polygenic model for AD, it could be hypothesized that an 
environmental component may contribute to the phenotype by interacting with the 
disease causing alle1es. In fact, under a polygenic model one must envi sion 
individual cases in which an unknown environmental component is solely 
responsible for the phenotype given that the concordance rate between MZ twins 
is less th an 100%. It must be mentioned that individual cases where an 
environmental component is the sole causal factor is not mutually exclusive to the 
DNM model, however under this model the factors outlined in section 3.1 are 
more likely to create this imperfect concordance. 
The DNM model largely precludes the role of an interaction between 
common genetic variants with an environmental component to produce the 
phenotype, however this does not eliminate an environmental component to AD. 
Environmental mutagens may raise a regional mutation rate, therefore predicting 
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that in regions such as Chemobyl, Nagasaki, and Hiroshima where an elevated 
level of environmental mutagens are present, a slightly increased incidence of AD 
would be discovered, although it is unlikely that such specifie localized 
epidemiological information has been tabulated. This also has an implication 
with respect to the recent increased prevalence observed with AD J3 . Future 
studies may definitively determine whether an increased incidence of AD is at 
least slightly responsible for an increased global prevalence of AD, and not 
entirely due to fluctuating diagnostic criteria. The DNM model wou Id imply that 
this increase would be due to an environmental agent that influences the mutation 
rate, although this contribution is likely to be slight. Examining other monogenic 
disorders that result largely from de nova mutations is unlikely to produce 
significant results as the genomic size upon which the specifie mutation may arise 
is very narrow. However, with AD, where hundreds of genes may produce a vast 
spectrum of similar phenotypes, an increased mutation rate would likely influence 
the overall incidence of the disease. AIso, in the case of an autosomal dominant 
mutation that produces variable expressivity, environmental components may 
influence the phenotype and expression of the mutant allele. 
3.0 Strategies and tools for gene identification 
As previously mentioned, the importance of determining the genetic 
architecture is extremely important as different strategies will be used in different 
scenarios. Under the polygenic model, association studies will be the method of 
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choice, with linkage studies ideally restricted to larger families. Under the genetic 
architecture of the DNM model, different strategies must be employed to identify 
mutations in genes that produce the AD phenotype, as linkage and association 
studies are based on linkage disequilibrium, which cannot be fruitful unless there 
is transmission of these genetic variants. 
To date, most research attempts to discover the underlying genetic 
component of AD have been based on a polygenic model using linkage analysis 
and association studies. 
3.1 Linkage analysis 
A general description of a classic linkage study is performed by examining 
the segregation of genome wide markers, either polymorphic micro satellite loci or 
single nucleotide polymorphisms (SNPs), through a large multiplex pedigree of 
affected and non-affected individuals. If these markers are examined in tandem, 
they allow the researcher to construct haplotypes whose transmission can be 
easily observed through the pedigree, and whose size becomes smaller with each 
transmission resulting from recombination events during meiosis. The selective 
transmission of sorne haplotypes to affected individuals vs. non-affected 
individuals allows the researcher to employa statistical analysis to determine the 
log of odds (LOD) that the disease allele, or mutation that causes the disease, is 
located within a given chromosomal loci on a specific haplotype. The LOD score 
will vary based on several conditions including the penetrance of the disease and 
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the type of analysis performed, and most importantly, the number of individuals 
in the pedigree. 
Large multiplex pedigrees are exceedingly rare for AD which would either 
result from the low penetrance and requirement of multiple disease alleles in the 
case of the polygenic model, or the low reproductive rates of individuals with 
highly penetrant de nova mutations in the case of the DNM model. Only one 
pedigree large enough to refine a haplotype interval to the point of mutation 
discovery has been identified worldwide, and was used to reconfirm the role of 
NLGN4 as one ofmany causal genes for AD l7 . The lack oflarge pedigrees has led 
to a linkage strategy that involves combining sib-pairs from multiple families to 
examine the co-occurrence of haplotype sharing between affected siblings, 
regardless of whether the shared haplotype is common between different families 
(as mutations in the same gene on different haplotypes could lead to the AD 
phenotype). This strategy has been historically effective at identifying mutations 
in genes that lead to single gene disorders in which the phenotype is highly 
selected against, however in the case of AD this strategy has led to severallinkage 
peaks scattered throughout the genome, none of which are corn mon to every 
study. The distinction must be made at this point to c1arify the difference between 
a single gene disorder of which the phenotype is clinically homogenous, and the 
DNM model for AD which states that a monogenic cause in multiple genes will 
account for the large spectrum observed in the clinically heterogeneous 
phenotype. The combination of sib pairs from multiple families has led to linkage 
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reports at several loci scattered throughout the genome. There are certain loci that 
have been replicated in more than one study located at 7q21.2-q36.2, 16p12.1-
p13.3, 6q14.3-q23.2, 2q24.1-q33.1, 17ql1.1-q21.2, lq21-q44 and 3q21.3-q2972• 
3.2 Family based association studies 
Association analysis is a powerful tool that can be used to identify 
common alleles in the population that may confer a risk for developing a 
particular disease. AIl association studies are based on the premise that a 
particular common marker in the gene pool (ideally a tandem segment of a 
particular arrangement of SNPs termed a haplotype) will be associated with the 
disease or in linkage disequilibrium with another variant that is associated with 
the disease. The most common type of association analysis used in AD research is 
the transmission disequilibrium test. This method examines the transmission of 
SNPs located within candidate regions from heterozygous unaffected parents to 
affected offspring. Transmission of a particular heterozygous SNP, perhaps a Cor 
T would be random, each allele being transmitted with a probability of 50%. 
However if only affected individuals are examined, an excess transmission of a C 
or T may be observed if a particular variant either contributes to the disease or is 
in linkage disequilibrium with a different contributing variant. This experimental 
strategy is beneficial as the effects of population stratification and requirement of 
population matched controls are eliminated, which can create false positives with 
traditional association analyses. This strategy bas been utilized in approximately 
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70 studies of AD cohorts as of August 2007 without leading to the identification 
of a single variant that is definitively associated with autism. 
3.3 High resoJution anaJysis of de novo copy number variation 
During the process of meiotic recombination, genetic information 1S 
exchanged between the maternaI and paternal chromosomes. This process IS 
beneficial from the evolutionary perspective as it breaks down linkage 
disequilibrium al10wing beneficial variants to escape negative selection of 
detrimental variants. However, it can often lead to cytogenetic anomalies su ch as 
duplications, deletions, and translocations. Depending on the genomic location 
and size that may affect several genes in tandem or in sorne cases may only 
involve a single gene. In many instances, the deletion or disruption of a gene may 
lead to the same phenotype as a point mutation that truncates the protein 
sequence. Therefore, techniques that provide high resolution of de novo copy 
number variation and chromosomal anomalies can he used to identify a region 
containing a gene of interest. The coding regions of this gene can then he 
sequenced in a cohort of autistic patients for the presence of point mutations as a 
means of validation. This strategy has heen successfully employed to identify 
mutations in SHANK341 • 
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3.4 Medical re-sequencing 
If the DNM model accounts for the majority of patients with AD, large 
scale multi generational candidate gene sequencing projects would be the most 
efficient approach to identify mutations that produce the AD phenotype. Although 
financial restrictions may currently be prohibitive, it is now possible to identify a 
subset of candidate genes that may confer susceptibility to AD. For example, 
direct sequencing of candidate genes based on interactome maps, or genes 
belonging to a specific pathway or cellular structure, such as the synapse are 
currently plausible, whereas whole genome re-sequencing of 192 patients is 
currently out of the scope of all research labs. The success of this strategy relies 
heavily on the number of genes being screened as well as the number of subjects 
used in the study, which is unfortunately a direct reflection of the amount of 
financial assistance available. As sequencing costs decrease, the identification of 
de novo mutations using sequencing technologies coupled with efficient 
functional validation will ultimately be the future of gene identification strategies 
for idiopathic genetic disorders under strong negative selection. 
3.5 Bioinformatics 
The sequencing, mapping and subsequent online availability of the human 
genome project in 2001 has led to greater simplicity in identifying genetic 
variants and mutations that lead to disease88, 89. This project has led to a 
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considerable amount of information that is currently managed through several 
user-friendly web-based programs such as the UCSC Genome Browser 
(www.genome.ucsc.edu). These web based tools allow researchers to visually 
examine genomic regions for candidate regions that would likely harbor a 
mutation that leads to a given phenotype. For example, in the case of AD, if 
linkage analysis were to identify a 20 megabase segment on chromosome 4 that 
segregates with the disease in a given family, this pro gram would allow detailed 
examination of genes located within this interval, intron/exon structure, 
expression information, promoter sequences, gene prediction tracks and 
evolutionary conservation among many other tools that would allow the 
researcher to make an informed decision regarding which regions are the best 
candidates for sequencing analysis. These tools also provide the user with a 
catalogue of known SNPs and microsatellites that aids the selection of suitable 
markers for association studies. 
3.6 Validation of genetic variants 
Although any two humans on the planet are 99.99% identical, this means 
that there are still approximately 12,000,000 variable genetic sites. This poses a 
difficulty in determining whether a SNP is responsible for producing a given 
phenotype. Therefore a validation process must be followed in order to determine 
the role of an identified SNP in causing the disease. The validation process is 
generally two fold, genetic and functional. 
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Genetic and statistical arguments should be satisfied before beginning 
functional work on a given genetic variant. For instance, many factors should be 
assessed depending on the type of study perfonned. As an example, in a large 
family linkage study, it should be detennined first if the variant is segregating on 
the disease hapIotype, and whether the variant is commonIy found in controIs 
(and if the proper control samples have been used). In the case of an association 
study, the sample size should be increased and replicated in different populations. 
For new mutations, care should be taken to detennine whether the proper parents 
were obtained, and wh ether this site is highly conserved among other populations. 
After genetic and statistical arguments have been satisfied, one would 
nonnally proceed with functional validation. This will vary widely depending on 
many factors including genomic location (promoter, enhancer, co ding region, 
splice donor/acceptor site). For example, if a rare mutation has been discovered in 
a promoter element, a luciferase assay would be perfonned to detennine the effect 
this variant has on expression. If a mutation were discovered in a splice donor 
site, RT-PCR would be perfonned on cell lines taken from patients with the 
variant to detennine whether the variant affects splicing. Although one may show 
that a variant displays a functional effect on the cellular level, it does not 
necessarily mean that it will on a phenotypic level, therefore animal models are 
often developed for the variant such as transgenic or knockout mice. 
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3.7 The French Canadian population as a sample cohort for AD 
The Rouleau lab has currently assembled approximately 600 DNA 
samples taken from patients with AD, of which ~ 70% are derived from the 
French Canadian (FC) population. These samples have been taken from patients 
that are have diagnosed according to DSM-IV criteria, administration of the ADI-
Rand/or ADOS-G and have participated willingly based on informed consent. 
The FC population is estimated to derive from a small founder population of 
3000-4000 individuals which arrived from southem France between the years 
1750-1850. Using a sample cohort derived from this population presents several 
considerations for gene discovery projects. This founder effect can pro vide 
benefits when one considers either the polygenic model or the DNM model. 
Under a polygenic model, the genetic variants that predispose to AD within the 
FC population wou Id be homogenous and likely increase the probability that the 
genetic basis of AD in the FC population is based on a homogenous group of 
genetic variants. Under the DNM mode l, the majority of cases would not be 
influenced by the founder effect as de nova mutations are equally likely to strike a 
genetically homogenous population as the y are a genetically diverse population, 
however transmission may occur via the mechanisms listed in Table l (page 19) 
and be more easily identified in a genetically homogenous population through 
haplotype sharing across multiple families. 
Unfortunately, the prematurity of the FC population also likely means that 
fewer recombination events separate the individuals of the population from the 
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founders. Therefore, positional cloning techniques are likely to identify large 
haplotype blocks with many candidate genes delaying the mutation discovery. 
4.0 Association study of the GABAA receptor subunit c1uster at 
15q12 in the French Canadian population 
4.1 Abstract 
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Chromosomal region 15q 11-13 has been consistently implicated in autism 
through numerous avenues such as maternaI duplications, breakpoints in the 
region and presence of autistic features in patients with Prader-Willi and 
Angelman syndrome90. Furthermore, linkage to GABRA3 within a cluster of 
GABAA receptor subunit genes has been previously described and replicated in 
different AD populations91 -93 . In this study, 185 trios were assembled with 
affected patients diagnosed according to DSM-IV criteria, administration of the 
ADI-R and/or ADOS-G. Genomic DNA was extracted from lymphocytes of 
patients, of which 70-75% are of French. Canadian origin. With an average 
spacing of 30 Kb, 26 SNPs spannillg 820Kb of the GABAJ\ receptor SUbUllit 
cIuster at 15q 12 were selected from the dbSNP and Celera databases based on 
minor aUele frequency >0.05, spacing and haplotype structure. A transmission 
disequilibrium test (l'DT) from the UNPHASED software suite was used to 
analyze the markers in question, 3 SNPs revealed a significant association 
including rs2873027. 
4.2 Introduction and rationale 
Gamma (À) aminobutyric acid (GABA) is the pnmary inhibitory 
neurotransmitter in the adult brain, but likely acts an excitatory neurotransmitter 
45 
during embryonic developmenë4. GABA plays an important role in signaling 
before, during and after synaptogenesis and synaptic maturation95 . It is also a key 
signaling factor that controls the early and late phases of neurogenesis inc1uding 
ceIl proliferation, migration and cell fate commitment followed by the late stages 
of maturation and synaptic integration95 . GABA interacts on the post synaptic 
membrane with a specifie receptor that varies with ceIl type. GABA sub A 
(GABAA) receptors are pentameric chloride channels composed of various 
subunits labeled from al- a6, ~1-~3, À1- À3, pl-p3, as weIl as 8,ê,8,1t 96,97. These 
subunits are found in several locations throughout the genome, however they 
combine in multiple permutations to pro duce very high functional heterogeneit/8. 
Examining these receptor subunits for a potential role in AD is warranted 
due to the role they play in synaptogenesis and synaptic maturation. Furthermore, 
suppression of GABAergic inhibition has been hypothesized to lead to the AD 
phenotype99 based on reduced binding of radiolabeled GABAA receptor ligands in 
autopsy brain specimens from individuals with autismlOO, as weIl as elevated 
levels of circulating GABA in children with autismlOl-103. 
The observation of autistic features in individuals with Prader-Willi and 
Angelman syndrome, as weIl as the observation of chromosomal re-arrangements 
in autistic patients at the Prader-Willi/ Angelman region at 15q 11-13 1 04-106 
initially led to the investigation of the GABAA receptor subunit c1uster located at 
15q 12, a 1.1 Mb region containing three GABAA receptor subunit genes 
GABRB3, GABRA5, and GABRG3 (Figure 1, page 48). Under the pretense of a 
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polygenic model, several studies have been performed on this region to examine 
association between common genetic variants and AD with mixed positive and 
negative results91 , 92, 107-115. 
The gene that has shown more consistent reports of association lS 
GABRB3. There have been reports of association with microsatelIite marker 
155CA-2 located near GABRB391 , 114. Recent studies have revealed five 
significant local p-values using SNPs across the gene92, as well as an association 
with a haplotype located within an intron of GABRB3 1 \3. There are several 
imprinted genes in the 15q 11-13 region, therefore a potential exists for imprinting 
at the GABAA receptor subunit cluster. Reports thus far have been conflicting 
with reports of bi-allelic expression in mice l16, as well as a patemal expression 
bias in humans l17, \18. A more recent report has shown that these genes are bi-
allelically expressed in humans, however maybe subject to epigenetic 
dysregulation in patients with AD and Rett Syndrome 1 19. 
4.3 Materials and Methods 
Clinical population 
Three hundred and three trios (father, mother, affected) were tested in this 
study, ofwhich 70-75% are of French-Canadian origin. Each affected patient was 
diagnosed with AD according to DSM-IV criteria using either the ADI-R and/or 
ADOS-G by at least one psychiatrist. Exclusion criteria from this study include a 
previous diagnosis or evidence of any psychiatric/neurological condition such as 
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Rett Syndrome, fragile-X syndrome, tuberous sclerosis, Tourette syndrome, or 
phenylketonuria. 
Blood samples were collected from each participating member (mother, 
father, affected offspring) followed by DNA extraction from lymphocytes. The 
study received ethics approval from the local ethics committee, and the 
participants or parents provided informed consent. 
SNP selection 
Twenty-six SNPs with an average spacmg of 30 Kb were selected 
spanning 820 Kb of the GABAA receptor subunit cluster at 15q12. These SNPs 
were selected based on minor allele frequency >0.05, potential functional 
candidacy, as well as distance from other selected SNPs to ensure adequate 
coverage and haplotype construction of the region. A distributional map of these 
SNPs is shown in Figure 1 (page 48). 
OASRS3 GASRA! OASR03 
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SNP's Studled 1 1 1 1111 Il 1 III Il Il Il 
McCauley et al. 2004 1 III 
Curran et al. 2006 11111 
166CA·2 
Location (Mb) 24.41 24.51 24.81 24.71 24.81 24.91 25.01 25.11 25.21 
Figure 1: Map of the GABAA receptor subunit cluster at l5q 12. The genes are displayed 
showing their approximate location represented as distance in Mb from the terminal 
segment of the small arm of chromosome 15. The structure of each gene is revealed 
with vertical strokes representing exons, and the 5' and 3' UTR represented as 
vertical strokes of intermediate length with arrows above revealing transcriptional 
orientation. The distribution of SNPs used in this study are displayed below the gene 
as vertical strokes that span 820 Kb of the total 1.1Mb represented in the diagram. 
The SNP rs2873027 who se association with AD has been replicated in this study 
from McCauley et al is shown in red. SNPs with positive local P-values within the 
GABRB3 gene are shown in red from McCauley et al, 2004. The 5 SNP haplotype 
whose excess transmission was observed in a patient cohort from Curran et al, 2006 
is represented in green. The microsatellite l55CA-2 whose association with AD has 
been observed previously is also shown in a separate colunm. 
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Genotyping 
One hundred and eighty-five trios were initially genotyped, however an 
additional 124 trios were genotyped at rs2873027. Twenty-six SNPs were 
selected for use in this study (see Table II, page 51). Genotyping was performed 
with a Taqman based allelic discrimination as say (Applied Biosyste.Q1s, Foster 
City, CA). The polymerase chain reaction (PCR) was carried out in a total 
reaction volume of 5 J.lI using the following amplification protocol: denaturation 
at 95°C for 10 min, followed by 40 cycles of denaturation at 92°C for 15 s, and 
annealing and extension at 60°C for 60 s. Post-PCR, the genotype of each sample 
was assigned automatically by measuring the allele-specific fluorescence in the 
ABI 7900 HT Sequence Detection Systems, using the SDS 2.2.2 software for 
allelic discrimination (Applied Biosystems). 
Statistical Analysis 
Statistical analyses were performed using the program TDTPHASE from 
the UNPHASED software suite, a pro gram written by Frank Dudbridge l20. 
UNPHASED is a program that performs genetic association analysis. It 
implements maximum-likelihood inference on haplotype and genotype effects 
while dealing with missing data such as uncertain phase and missing genotypes. 
The transmission/disequilibrium test (TDT) was developed in 1996 as a 
test for linkage disequilibrium l21 . The test is based on the principle that the 
probability of transmission oftwo different marker alleles [rom unaffected parents 
q 
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to affected offspring will be significantly higher when the marker locus and the 
hypothetical disease locus are linked and are in linkage disequilibrium. When 
SNPs are used as the marker allele, it is therefore important to use SNPs with 
relatively similar population frequency to boost the number of heterozygous 
parents. This test is effective at identifying loci with less penetrant effects on the 
phenotype. 
4.4 Results 
Examination of local p-values from 26 SNPs across an 820 Kb region 
revealed three sites with significant transmission disequilibrium, p<0.05: 
rs2873027, rs6606905, and rs8043244 (Table II, page 51). Furthermore, three 
SNPs with relatively low p-values were found: rs75415 (0.08414), rs140682 
(0.065482) and hCV42974 (0.08873) (Table II, page 51). Interestingly, an excess 
transmission of the C allele from SNP rs2873027 was observed in the initial 
screening of 179 families. Considering the previous results from McCauley et. 
al92, as weIl as the excess transmission of a haplotype in linkage disequilibrium 
with this variant from Curran et. al 113 , an additional 124 trios were screened for 
transmission disequilibrium at rs2873027 and added to the initial cohort of 179, 
for a total of 303 trios genotyped at rs2873027 (Table III, page 52). The p-value at 
this site increased from a significant 0.01246 to a non-significant 0.2894. 
Table II: Results obtained from the TDT. The two columns on the left are the SNP references 
from the dbSNP and Celera databases. Empty fields represent SNPs found solely within 
one database. The distribution of these SNPs from top to bottom are shown from left to 
right on Figure 1. Transmissions (T) and non transmissions (NT) are listed along with 
the identity of the corresponding SNP for the significant as well as lower p-values. The 
furthest column on the right is the p-value obtained in previously published studies 
(PPS). • denotes significance at the 95% level. 
Marker dbSNP Celera Gene SNP p-value T NT Allele 
1 rs11637141 hCV2911915 GABRB3 clt 0.851258 
2 rs1426217 hCV2901088 GABRB3 a/g 0.3887 124 114 9 
3 rs1426208 hCV2901113 GABRB3 clt 0.2529 
4 rs2873027 hCV2901140 GABRB3 cft 0.01246" 179 149 e 
5 rs754185 hCV2901163 GABRB3 clt 0.08414 193 173 e 
6 rs12912421 hCV2901117 GABRB3 a/g 0.7423 
7 rs890317 hCV8865209 GABRB3 ale 0.6656 
8 rs11631421 hCV245488 GABRB3 clt 0.4336 
9 rs919075 hCV8864788 GABRB3 clt 0.1732 
10 rs11161335 hCV9399204 GABRB3 aIt 0.1915 
11 rs8179184 hCV276328 inter clt 0.3186 
12 rs8032064 hCV416499 GABRA5 clt 0.3715 
13 hCV42974 GABRA5 clt 0.08873 114 94 t 
14 rs140682 hCV1028938 GABRA5 clt 0.06564 196 173 e 
15 rs140685 hCV1028939 GABRA5 clt 0.8066 
16 rs6606905 hCV2078439 GABRG3 clt 0.04957" 196 184 t 
17 hCV2078482 GABRG3 clt 0.2675 
18 rs2376483 hCV2078528 GABRG3 a/g 0.8048 
19 rs1432126 hCV8865801 GABRG3 clt 0.634 
20 rs1029937 hCV2665757 GABRG3 a/g 0.4182 
21 rs6606877 hCV2665737 GABRG3 cIt 0.2162 
22 rs2286946 hCV2665715 GABRG3 a/g 0.905 
23 rs208126 hCV2665687 GABRG3 g/t 0.2059 
24 rs897173 hCV9408511 GABRG3 a/g 0.8403 
25 rs8043244 hCV9408423 GABRG3 a/g 0.03936" 112 88 9 
26 hCV435176 GABRG3 a/g 0.7394 
PPS 
0.21 
0.04" 
0.82 
0.94 
0.21 
0.08 
0.65 
0.84 
0.21 
0.94 
0.6 
0.66 
0.16 
0.06 
0.25 
1 
Table III: 
Marker 
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TDT results of an additional 124 trios were genotyped at SNP 
rs2873027 bringing the total to 303. The p-value increased 
from 0.01246 to 0.2894 
dbSNP Celera hCV 
rs# # Gene SNP p-value T 
rs2873027 hCV2901140 GABRB3 cft 0.2894 297 
NT Allele 
280 C 
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4.5 Discussion 
In the initial screemng, three SNPs showed significant transmission 
disequilibrium (p<0.05), rs2873027, rs6606905 and rs8043244, and three SNPs 
revealed lower p-values: rs754185 (0.08414) hCV42974 (0.08873) rs140682 
(0.06564). AlI of these values must be examined with caution as the y have not 
been corrected for multiple testing. 
Our initial screen replicated previous work by McCauley et. al92, showing 
a significant transmission disequilibrium for SNP rs2873027. It is also noteworthy 
that work by Curran et. al l13 showed significant transmission of a haplotype 
located 10 Kb upstream in linkage disequilibrium, however they did not include 
that particular SNP in their study. The inclusion of 124 additional trios totaling 
303 trios at this site increased our p-value to 0.2894, questioning the replication 
and presents several scenarios which will need to be examined based on the 
polygenic and DNM model. This SNP is located within an unconserved region of 
intron 3 approximately 700 bp from the intron/exon boundary of ex on 3. 
Under the polygenic model, our results imply that, although this variant or 
a variant in linkage disequilibrium may contribute to the autism phenotype, it is 
clearly not required, and may only contribute to a small proportion of overalI 
cases. Given that this gene encodes a GABA receptor subunit that interacts with 
several other subunits to create a functional receptor, a potential exists for 
rs2873027 to be in linkage disequilibrium with a common coding variant from 
exon 3 that interacts with another coding variant from a partnering subunit to 
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produce the phenotype. However, this potential is slight given that exon 3 is 
perfectly conserved among mammals, and no SNPs have been documen~ed within 
it in humans. The potential for variants to co-exist through hundreds of ancestral 
generations that produce phenotypes under strong negative selection has been 
addressed in section 2.4. However, sequencing of this exon was not performed on 
individual cases in this study 
Interpreting these results under the DNM model requires a slightly more 
abstract approach. Assuming that the association to rs2873027 as weil as the 
haplotype in linkage disequilibrium with this SNP from Curran et. al 113 , is 
functionally relevant and not a result of multiple testing, this association would 
stem from a recessive locus or from an association with a haplotype that has a 
tendency for non allelic homologous recombination (NAHR), which ·results in 
functional de nova deletions within this region. This could easily be imagined if 
the associated haplotype contained several extra repeats that would initiate 
homologous recombination with a downstream repeat resulting in a duplication or 
deletion. This is not an unprecedented mechanism, as several examples currently 
exist that lead to human genetic disorders 122- 127 . Given the frequency of abnormal 
karyotypes in AD patients carrying duplications or deletions in this region, it is 
plausible that smaller scale duplications/deletions would produce the AD 
phenotype as weil. Future techniques providing higher resolution of DNA copy 
number variants (CNVs) within this region in multiple patients containing the risk 
haplotype, may decipher whether this mechanism underlies the association to 
. i 
, !; 
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rs2873027. However, the risk haplotype must first be properly characterized and 
identified through denser marker spacing in order to limit the cost of such a 
procedure, as simply screening multiple patients that contaÎn a C at SNP 
rs2873027 would be quite inefficient. 
The t allele from rs6606905 was transmitted in excess with slight 
significance (p=0.04957). This SNP lies within intron 1 of GABRG3 
approximately 1,000 bps from exon 1. We are unaware of the inclusion of this 
SNP in previous studies, however there have been no previously reported 
associations with any markers that would be in strong linkage disequilibrium. 
Replication from future studies will be required to pursue the nature of the 
association with this SNP any further. 
Slightly significant excess transmission (p=0.03936) was also observed for 
the g allele from SNP rs8043244. This SNP is located within an unconserved 
region of intron 3 from the gene GABRG3. This SNP has been included in 
previous studies with a non significant p-value of 0.2592• Replication is required 
from future studies to determine if this association is functionally relevant or a 
chance result of multiple testing. 
4.6 Conclusion 
This study was performed to identify variants within the GABAA receptor 
subunit cluster, which may contribute or predispose to the AD phenotype. In 
addition to identifying an association with two SNPs that have not been reported 
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in the literature, some additional support has been given to the association of 
rs2873027 with AD. These results must be replicated in different populations for 
further validation. 
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5.0 Investigating the role of polyalanine expansions/contractions 
in AD 
5.1 Abstract 
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Polyalanine repeats are under increasing scrutiny as they have been 
discovered to be involved in an increasing number of genetic disorders. In this 
study, 56 alanine repeats were screened for variants in 192 patients diagnosed 
with AD according to DSM-IV specifications and 192 control s, in an attempt to 
determine a link for alanine repeats with AD. This led to the identification of 
several interesting genetic variants from seve raI genes including ZIC2, TBLXRJ, 
ARIDJA, POUF3 and FOXD3. 
5.2 Introduction and rationale 
Repetitive stretches of DNA are found throughout the human genome and 
are prone to intergenerational expansions and contractions due to their 
susceptibility to slipped strands during replication as well as unequal homologous 
allelic recombination. These expansions and contractions are generally neutral in 
the case of microsatellite DNA, however the y can have phenotypic consequences 
if the y produce a functional effect. These phenotypic consequences can lead to 
human genetic disorders, of which a growing class termed trinucleotide repeat 
disorders (TRD) is already weIl characterized. TRDs are the reslJlt of the 
expansion of nucleotide triplets and can be classified into three categories based 
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on the distinct disease mechanisml28. In the first category, repeat expansions in 
non-coding sequences generally result in decreased transcription and mRNA 
formation. For example, the expansion of the (CGG)n repeat in the 5' UTR 
promoter region of FMRI results in hypermethylation and transcriptional 
repression which leads to Fragile-X Syndrome 129 . Secondly, expansions in coding 
but non-translated sequences can cause complex RNA pathology130 as in the case 
of myotonic dystrophyl31. The third category is the expansion of translated 
sequences coding for poly-amino acid tracts that lead to toxic mis-folded proteins, 
, " 
l' 
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, which is the most common disease mechanism leading to several human diseases. 
For example, the expansion of CAG repeats in the coding portion of the 
Huntingtin gene lead to the formation of a protein with a large toxic stretch of the 
amino acid glutamine. Expansion of polyalanine tracts have also been linked to 
human disease. To date, nine genes with polyalanine tracts have been identified 
for which an identifiable human disease has been found (Table IV, page 61). 
1 
1 !, 
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Although the function of these polyalanine stretches has not been determined, 
, 
they are over represented in transcription factors, particularly those expressed 
during development. This fact presents itself when one looks at the list of genes 
involved in hum an disease from Table IV (page 61), as every gene aside from 
P ABP NI is a transcription factor. 
When one compares the location of the polyalanine tract within the gene, 
as well as the length of the repeat among mammals, considerable conservation is 
1 il 
generally observed, which implies that there has been strong negative selection 
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against de nova mutations that produced any considerable functional or structural 
changes at the prote in level. Alanine is encoded at the genetic level by the codon 
GCN, where N represents any of the four nucleotides. Therefore, the third base 
pair can also mutate freely and drift to fixation without producing a functional 
consequence on the protein level. As a consequence, the majority of alanine 
stretches are impure heteropolymeric repeats (e.g. GCCG)GC(C)GCCC)-
GC(A)GCCT)), whereas the repeats found in other TRDs are pure homopolymeric 
repeats (e.g. CAGCAGCAGCAG) This explains why the expansion and 
contraction of polyalanine tracts are a result of unequal allelic homo logo us 
recombination during meiosis 132, whereas the expansion observed in other TRDs 
are likely a result of polymerase slippage during replication. This differing 
mutational mechanism leads to far less extreme shifts in repeat length for 
polyalanine tracts versus other trinucleotide repeats. For example, in the 
Huntingtin gene, the CAG repeat length can vary in the normal range from 6-35 
and from 40-121 in the disease range 133 , and in the case of FMRI the number of 
CGG repeats can vary enormously with the pathological range greater than 200 
repeats l34 . In polyalanine disorders, the upper range in repeat length is always 
below 30 and the difference between wild type and disease length is far more 
subtle with ranges between 1-14 128 . As an example, in the case of ocular 
pharyngeal muscular dystrophy (OPMD), the wild type length of the polyalanine 
tract in the PA BP N 1 gene is 10 with the mutant allele ranging from 11-17 
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The pathological mechanism for the majority of polyalanine disorders is 
currently believed to be caused by protein misfolding128• The general concept is 
that mis-folded protein will form cytoplasmic aggregates that exceed their 
degradation and can interfere with the wild type protein, possibly explaining the 
dominant nature of many of these mutations. Mutant ARX (mutations in which 
have been discovered in patients with AD) also form aggregates, but these appear 
to occur predominantly in the nucleus of affected cells rather than the 
1"6 cytoplasm Cl • 
This type of pathology has generally led to adu1t onset disorders, however 
glven the frequent appearance of the se polyalanine repeats in embryonic 
transcription factors it had been theorized and recently shown that these alanine 
repeats are involved DNA binding as weil. Deletions in the C-terminal alanine 
repeat of ZIC2 have been shown to decrease its DNA binding efficiency137. 
Genes with polyalanine repeats are leading candidates for the investigation 
of a role in AD for several reasons. The majority of these tracts are found in 
embryonic transcriptions factors that are involved in neurological and 
physiological development, representing candidate genes for syndromic and non-
syndromic forms of AD. Polyalanine repeats are also highly conserved in 
mammals in terms of length and site, as expansions of a single repeat have been 
shown to cause disease. Therefore slight variations in the se tracts may produce 
profound phenotypic consequences. Considering that the majority of the se genes 
are transcription factors, it is possible that slight variations in alanine length affect 
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protein folding and create functional differences that influence expression levels, 
which may trigger cascading events during embryological development. 
The mutation rate of tandem DNA repeats has been estimated to be greater 
than 100,000 times that of a point mutation55, Although this represents the 
mutation rate of pure tandem repeats, the mutation rate of polyalanine stretches is 
undoubtedly greatly increased as weIl, and is a function of the repeat length, as 
longer repeats are generally less stable and more prone to expansion/contraction. 
A higher mutation rate coupled with the degree of conservation in the se repeats 
implies that although de nova mutations are common, there is a considerable 
degree of selection against the resulting phenotype. This fits perfectly within the 
framework of the DNM mode\, however it is still possible that under a polygenic 
model, common variations of alanine repeat length can lead to, or predispose to 
the AD phenotype. 
Table IV: List of gencs whose alanine tracts have been implicated in human disease. 
Given the clear potential for polyalanine expansion and contractions to be 
implicated in the phenotype of AD, this study was designed to perform an initial 
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broad screen of a fraction of alanine repeats in patients to compare with the 
normal population. If this study provides interesting results, it will lead to future 
screening of additional variants and functional studies. Furthermore, alanine 
expansions and contractions represent an important class of coding genetic 
variation within humans that has not yet been catalogued. Therefore, another 
outcome of this study will be to catalogue much of this variation. 
5.3 Materials and Methods 
Gene Iist 
Online bioinformatics programs available at the NCBI database 
(http://www.ncbi.nlm.nih.govIBLAST/) were used to develop a list of genes 
within the scope of this project using the Blast-P algorithm. The Blast-P search 
tool examines the co ding portions of proteins for matches against the users search 
query. Tandem alanine repeats can vary in length from 2-20 with the higher repeat 
lengths decreasing in frequency, therefore criteria were established to determine a 
gene's candidacy for this project. The gene list was balanced on two main criteria, 
alanine repeat length and functional candidacy of the gene. Longer repeat lengths 
are less stable therefore an alanine repeats greater than ten were preferentially 
selected for this project, however several genes were selected with repeat lengths 
lower than this threshold based on functional candidacy with the shortest repeat 
length at five tandem alanine residues. Several of the genes contained more than 
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one alanine tract that were examined separately. In aIl 56 alanine tœcts were 
successfully screened in this study. 
Clinical population and con trois 
One hundred and ninety-two patients as weIl as 192 controls were selected 
for initial screening of these 56 selected alanine repeats. An additional 161 
patients and approximately 460 additional controls were screened for variants that 
revealed rare polymorphisms. Each affected patient was diagnosed with AD 
according to DSM-IV criteria using either the ADI-R and/or ADOS-G by at least 
one psychiatrist. Exclusion criteria from this study include a previous diagnosis or 
evidence of any psychiatric/neurological condition such as Rett Syndrome, 
fragile-X syndrome, tuberous sclerosis, Tourette's syndrome, or phenylketonuria. 
Blood samples were collected from each participating patient followed by DNA 
extraction from lymphocytes. The study received ethics approval from the local 
ethics committee, and the participants or parents provided informed consent. 
Determining alanine repeat lengths 
Repeat lengths were determined by radiolabeled (alpha-35S)-dATP PCR 
amplification of genomic DNA using primers that surround the alanine repeats. 
The PCR reactions were performed with 75-150 ng of genomic DNA; the primer 
sequences and PCR reaction conditions are available upon request. These PCR 
products were run on 6% denaturing polyacryJamide gels and compared with the 
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product of a di-deoxy sequencmg reaction to determine the length of the 
amplicon. This provides a rough but accurate assessment of the repeat length of 
the alanine residues, however aIl rare variants were directly sequenced to produce 
a more accurate representation of the repeat length, as weIl as to certify that the 
variations of amplicon length were a direct result of variations in the alanine 
repeat length. Furthermore a sample was sequenced from each of the other tracts 
1 1 as weIl to ensure that the correct fragment had been amplified. 
5.4 ResuUs 
In al!, 56 alanine repeats were successfully screened. The results of this 
screening created a natural categorization of these alanine tracts based on degree 
of variation and potential for disease aIlele based on discrimination between cases 
and controls: 1) alanine tracts which revealed no variation (Table V, page 65), 2) 
1 ii 
alanine tracts which were highly polymorphie with no identifiable wild type, 
(Table VI, page 65) 3) alanine tracts which had a clearly identifiable wild type 
repeat length with slight variations that were similar in cases and in controls 
(Table VII, page 66), 4) rare variants present in AD patients with llttle to no 
presence in controls (Table V III , page 66). Several of the genes contained 
multiple alanine tracts therefore this is specified by noting if the repeat was 
1 
located at the N-terminal, middle, or C-terminal end of the protein. 
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Table V: Gene list for which no variations in alanine length were determined. Several genes contained more 
than one repeat therelore this is specified in sorne cases by noting the location within the protein. 
Gene Locus Repeat length 
PBX3 9q33-q34 9 
SOX3 Xq27.1 C-terminal 10 
POU4F1 13q31.1 10 
EN1 2q14.2 10 
DACH 13q22.1 9 
RBM9 22q13.1 8 
SOX21 13q32.1 N-terminal 10 
ZIC2 13q32 central tract 
ZIC2 13q32 N-terminal 9 
HOXD13 2q31.1 6 
FLJ23342 11 q24.2 8 
CRSP2 Xp11.4 8 
MECP2 Xq28 5 
GSH-2 4q 11-q12 16 
TBX1 22q11.21 15 
LHX2 9q33-q34.1 10 
OLlG2 21q22.11 13 
SWAP2 19q13.32 10 
HSRNAFEV 2q35 12 
CHD3 17p13.1 10 
ZBTB8 1 p35.1 15 
DMRTAt 9p21.3 11 
NLK 17q11.2 13 
ZICS 13q32.3 N-terminal 9 
Table VI: Gene list for which no discernible wild type repeat length was observed, therefore the repeat 
numbers given are approximations. Several gcnes contained more than one repeat therefore this is 
specified in sorne cases by noting the location within the protein 
Gene Locus Repeat 
size 
SOX21 13q32.1 C-terminal -12 
PRKCM 14q11 -10 
ASCL1 12q22-q23 -13 
NIPA1 15q11.2 -13 
Given the potential for common alanine repeats within these genes to be 
involved in the AD phenotype as a polygenic contributor, the allele and genotype 
1 r ~ 
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frequencies were tabulated within the patient populations were tested for Hardy-
Weinberg equilibrium with no significant deviations. 
Table VII: Gene list for which several variants were observed whose frequencies matched those found in 
controls. Several genes contained more than one repeat therefore this is specified in some 
cases by noting the location within the protein. Several genes contained more than one repeat 
therefore this is specified in some cases by noting the location within the protein. 
Gene Locus Repeat size 
SOX3 Xq27.1 N-terminal 15 
HOX013 2q31.1 15 
GUCY1A2 11q21-q22 8 
HOX08 2q31.1 9 
/GSF4 11q23.2 8 
AR/01B 6q25.1 11 
HOX013 2q31.1 15 
NKX2-4 20p11 16 
EGR2 10q21.1 10 
E/F4G3 1p36.12 16 
Z/C5 13q32.3 C-terminal 9 
PTBP2 1 p21.3 10 
TLE4 9q21.3 11 
K/AA0601 1p36.12 12 
ASCL1 12q22-q23 13 
R/S1 3p21.3 14 
ASXL2 2p24.1 13 
FBX041 2p13.2 11 
AR/D1B 6q25.1 11 
NKX2-3 10q24.2 16 
Z/C3 Xq26.2 10 
SOX21 13q32.1 Central Tract 13 
Table VIII: List of alanine tracts who se rare variants were observed in patients and and unmatched in 
controls. Several genes contained more than one repeat therefore this is specified in some 
cases by noting the location within the protein. 
Gene Locus Repeat size 
Z/C2 13q32 C-terminal 15 
TBL1XR1 3q23 11 
POU3F3a 2q12.1 N-terminal 12 
POU3F3b 2q12.1 C-terminal 16 
FOX03C 1p31.3 N-terminal 11 
AR/01A 1p36.11 11 
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Ali variants from Tables VII and VIII (page 66) were verified by direct 
sequencing of peR amplicons to ensure that fragment length variation on 
polyacrylamide gel were a result of alanine expansions/contraction and not an 
artifact or insertionldeletion of a different region. This is shown in Figure 2 (page 
68) for the ZlC2 C-terminal alanine deletion and Figure 3 (page 69) for the 
TBLXRl (alternative name IRAl) alanine expansion. Although ail variants were 
screened in 192 patients and 192 control s, further screening of patients and 
controis was performed where possible of tracts listed in Table VIII (p;lge 66) in 
an attempt to identify the rare variants found in larger sample cohorts. 
ZIC2 was screened in 342 patients and a single large deletion was 
observed that was not seen in 384 controls (768 chromosomes). The N-terminal or 
5' alanine repeat of POU3F3 was screened in 342 patients as well as 192 patients 
(384 chromosomes) revealing a heterozygous deletion of seven alanines (12-5) in 
a single patient that was not observed in any controls. The C-terminal or 3 'alanine 
tract of POU3F3 (BRN-l protein) is larger containing 16 alanines and was 
screened in 342 patients with AD and 192 controls (384 chromosomes). A 
heterozygous deletion of two alanines (16-14) was observed in one patient that 
was not observed in 384 control chromosomes. The C-terminal alanine repeat of 
FOXD3 was screened in 384 patients and 192 controis (384 chromosomes) and an 
expansion of 4 alanines was observed in one patient not seen in controis. ARIDlA 
was screened in 192 patients and 192 controls and single deletion of seven 
alanines was observed in one patient that was not observed in controls. 
, i, 
Al~ Ala Ala Al~ Ala Al~ Ala Ale Ale Ala 
Pz:O Ala Ale Ala Ale. Ala V al Sel: 
__ .r----"'" 
Z/c2 patemal sequence 
Zic2 affected sequence 
ZIc2 wild type 
_--=;~~~b 
CAGCGGCGGCGGCAGCGG-------------------------- - -TGTC 
eaqeqqcggcgqceqeqqcgqcqqcqqetqcqgcqqcqgcggccqcgqegtc 
Figure 2: Sequence results showing an in frame 30 bp deletion in the affected offspring 
and the unaffected father resulting in a 15-5 deletion of 10 alanine residues. The reading 
frame consists of a six 5 alanines followed by a valine. The wild type protein contains 15 
alanines followed by a valine residue (the program placed the first position valine codon 
(guanine) at the 5' end of the deletion, whereas it could have aligned it at the 3' end with 
equal merit given the wild type has a G at either end. 
Ala A18 A1a Ale. A1a A1a 
IRA 1 wlld type 
Ale. Ale. Ale. A1a Ale. Al 8 A1a Ale. Ale. Ale. Sel G1n Gln Gly Sel 
CAGCAGCTGCTGCAGCTGC------------------CGCAGCTGCAGCCAGCCAACAAGGATCTGC 
~wJ~fVvv'M 
CAGCAGCTGCTGCAGCTGCAGCAGCTGCTGCAGCTGCCGCAGCTGCAGCCAGCCAACAAGGATCTGC IRA1 Affected 17619 
~ 
CAGCAGCTGCTGCAGCTGCIIGCAGCTGCTGCIlGCTGCCGCAGCTGCIIGCCAGCCAANNAGGATCTGC IRA1 Affected 24626 
IRA1 Affected 18442 ~MfYJ\M~ 
CAGCAGCTGCTGCAGCTGCAGCAGCTGCTGCAGCTGCCGCAGCTGCAGCCAGCCAACAAGGATCTGC 
Figure 3: Sequence results showing an in frame insertion of 18 bp's resulting in an expansion from 11-17 
alanine residues in three unrelated French Canadian patients. The patients were ail heterozygous however 
the alleles were separated on an agarose gel allowing the two copies to be sequenced individually. 
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TBLXRl was screened in 384 patients and over 500 population matched 
controls (> l ,000 chromosomes). A heterozygous expansion of six alanines was 
observed in three patients of French Canadian origin that was not observed in any 
controls. Given the similar family background, microsatellite markers were 
genotyped at eight markers surrounding the expansion to determine whether the 
mutation was identical by descent (IBD). The resulting haplotype construction 
(Figure 4, page 70) confirmed that the expansion had a single point of origin that 
had been transmitted through several generations. None of the families reported a 
history of AD. 
175'17 '17518 18440 18446 24629 24627 
0381565 1 ." 1 2 1 2 3 Î 1 3 4 2 .:::.. '-
0352421 2 ...., 8 6 5 5 3 "7 7 6 2 7 
" 
1 
0382312 5 5 1 5 5 5 4 5 5 4 7 ::) 
0383041 6 ~ 5 5 5 5 4 ~ 5 7 3 ::; ~J 
TBLXR1 VVT" li VVT VVT VVTVVT VVTV VVTVVT VVTV 
0382412 5 8 1 5 1 4 1 2 5 1 1 
0383037 8 7 8 4 9 9 7 7 5 8 5 7 
D383511 1 3 3 1 3 1 1 3 1 3 '1 
0383565 3 1 1 1 1 3 1 1 2 1 1 
17519 18442 24626 
2 2 1 '~I ..:::' 1 ") L 
7 6 5 "7 7 .. , 1 
" 
~) 5 5 5 5 5 
~~ 5 5 ~) 5 5 
V VVT wr \/ VVTV 
1 1 5 2 1 
7 4 9 7 5 7 
1 3 1 1 3 
1 1 1 1 1 
Figure 4: Haplotype construction of region surrounding TBL'(R 1 alanine variant in three French Canadian 
trios carrying a six alanine expansion. The haplotype containing the alanine variant (V) was 
transmitted from the mother in one family (17518) and the tàther in the other two families 
( 18446, 24627). The normal allele is labeled as wi Id type (WT). 
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5.5 Discussion 
The tract list from Table V (page 65) shows that 24 of the 56 alanine tracts 
that had been screened revealed no variation in alanine repeat length among our 
192 patients and 192 controls. There does not seem to be any correlation between 
alanine repeat length and degree of variability. Although local recombination 
rates may influence the mutation rate, the high degree of conservation is most 
likely a direct reflection of extreme structural and functional constraint on these 
sequences. Even though this group revealed negative results within the scope of 
this project, it is likely that future studies may discover that de nova polyalanine 
expanSIOns or contractions are the causal role for a genetic disorder which lS 
under strong negative selection or result in embryonic lethality. 
Table VI (page 65) displays a list of four alanine tracts that were 
extremely polymorphic, containing no identifiable wild type length with several 
observed repeats. The frequencies of these alleles were compared in patients and 
control s, and the genotypes were examined for Hardy-Weinberg equilibrium 
within the autistic cohort to examine the possibility that certain combinations of 
alanine repeat lengths within these genes conferred a risk to developing the AD. 
This comparison did not produce any significant results. Although this reveals 
that these genes are provided with a degree of structural flexibility in terms of 
fi 
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1 
polyalanine length, it does not necessarily follow that the variations produce no 
, " 
functional effect. Previous work has suggested that alanine repeats may provide a 
mechanism for rapid morphological evolution, and therefore may represent an 
l ' 
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important class of human genetic variation l46 . Future studies could focus on the 
allele and genotype frequencies of the alanine repeat variants between different 
populations to identify common variants that may be associated with common 
phenotypic variation between population groups. 
Table VII (page 66) contains a li st of alanine tracts with a clearly 
identifiable wild type length, which revealed several variants that were matched in 
the control populations. As mentioned above, although these variants could not be 
linked to the AD phenotype, these are rare co ding variants that may have a 
phenotypic effect not identified within the scope ofthis study. 
Table VIII (page 66) contains a list of genes whose rare variants were not 
observed in controls. It is worth noting that rare variants were observed in the 
control samples, which were not also observed in patients. Consequently, 
placement in this group is not a definitive link to the AD phenotype, it simply 
means that further screening of controls and patients is warranted. The work that 
has been performed to date on the genes within this group is summarized below. 
A large 30 bp, deletion of 10 alanines (15-5) was discovered in the C-
terminal alanine repeat of the ZIC2 gene in one patient within the initial 192 
affected sample cohort. This was not observed in our initial 192 controls. We 
subsequently screened an additional 150 AD subjects as well as an additional 192 
population matched controls without observing this variant again. This resulted in 
a total of 1/342 patients and 0/384 controls. Given that this mutation would be 
producing the phenotype in a heterozygous manner, these numbers could be 
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looked at in terms of number of chromosomes: 1/684 patient chromosomes and 
0/768 control chromosomes. Furthermore, this alanine stretch was perfectly 
conserved with the exception of this deletion. The N-terminal alanine stretch as 
weil as the central alanine tract within ZIC2 also revealed no variation in 192 AD 
patients and 192 controls. ZIC2 belongs to a group of transcription factors termed 
"zinc finger of the cerebellum", which are involved in the development of neural 
tissues and the neural crest, left-right axis patterning, somite development, and 
fomlation of the cerebellum 147. Interestingly, expansions of this C-terminal 
alanine tract are frequently observed in patients with holoprosencephaly (HPE)140. 
As this phenotype can be highly variable and lead to mental retardation, a patient 
with a lack of dysmorphic features could be misdiagnosed with AD. 
The family of the patient with the ZIC2 deletion reported no family history 
of AD or holoprosencephaly. Acrylamide gel electrophoresis as weIl as 
sequencing of DNA taken From lymphoblasts confirmed that the deletion had 
been transmitted From the unaffected father. This presents three possible 
scenarios: 1) the mutation is not related to the phenotype, or does not act 
dominantly to produce any phenotype, 2) the father is somatically mosaic for the 
mutation, which is a strikingly common scenario for expansions of this C-temlinal 
alanine tract l48, or the mutation occurred in the father's mother and the gene is 
maternally imprinted, 3) this rare variant requires other genetic or non-genetic 
factors that were not present during the father's development to produce the 
phenotype. Due to the severity of the mutation, the function of the gene involved, 
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and the presence of expansions within this alanine tract that produce dominant 
phenotypes, it is likely that this mutation is responsible for the phenotype. 
However, the rare presence of this mutation indicates that mutations in ZIC2 are 
not like1y to explain a large proportion of AD cases. It is worth noting that the 
father's male sibling is dyslexie and aIl of his children have learning disabilities, 
however DNA is unavailable from them at this time. Further examination of this 
mutation to identify potential paternal somatic mosaicism, screeniIi.g of the 
paternal family and siblings as weil as a functional study of this given mutation is 
1 
required to be certain of the phenotypic role this mutation has on the phenotype. 
1 
An 18 bp, six alanine expansion (11-17) was observed in an alanine tract 
from TBLiXRi (alternative name IRAi, TBLRi) in three heterozygous patients 
diagnosed with AD. This alanine tract was perfect1y conserved among human 
patient samples. This variant or any other alanine length variants were not 
observed within this gene in > l ,000 control chromosomes, whose primary origin 
is French-Canadian, French as weil as many from mixed ethnie backgrounds. 
,1 
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TBLXR1 is one of 10-12 proteins within the N-CoR complex J49 . In vitro, this 
protein binds histones H2B and H4, resulting in transcriptional repression. To 
1 li 
1 
date, this gene has not been implicated in any human disease. 
Ali three heterozygous patients were of FC origin, with the alanine tract 
1ength variant having been inherited paternaIly in two cases and maternaIly in 
one. Genotyping of microsateilite markers surrounding this rare expansion 
revea1ed that it was identical by descent (IBD), however these families could not 
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be connected by an immediate common ancestor. This finding presents 
implications when interpreting our results, as it implies that the expansion was not 
only inherited from unaffected parents but also that it has been transmitted 
through several generations of unaffected individuals despite the non appearance 
of the variant in >500 controls of which a minimum of 1/5th are of French 
Canadian origin. Therefore, there are three possible scenarios for the contribution 
of this variant to the AD phenotype: 1) This relatively rare variant interacts with 
another variant not present in unaffected family members to produce the AD 
phenotype 2) this rare variant interacts with an environmental agent that the 
previous family members were not exposed to 3) this variant does not contribute 
to the AD phenotype. Determining which of these three scenarios is correct may 
potentially prove to be very difficult. Simply performing a functional study on the 
: li effect of this variant on the gene product may give unsatisfying results. For 
example, a study on this variant that revealed no functional impact in a cellular or 
animal model would not necessarily be conclusive that it does not have a 
functional impact in the presence of another genetic component or environmental 
agent. Therefore, the validation of rBLXRI as a contributing component to the 
AD phenotype may need to come through replication from different global 
populations. 
POU 3 F 3 located at 2q 12.1 encodes Brn-I, a brain expressed transcription 
factor containing two separate alanine repeats, an N-terminal repeat of 12 alanine 
repeats and aC-terminaI repeat of 16 alanines. This gene belongs to a family of 
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genes involved in development termed the POU specific homeobox DNA binding 
domain. This particular prote in is also functional candidate for AD as it plays a 
critical role in neurogenesis acting as a transcriptional activator of Delta1 150• To 
date, mutations in this gene have not been implicated directly in any human 
genetic disease, however the gene is highly conserved in mammals meaning that 
severe mutations would likely result in embryonic lethality. 
The N-terminal, or 5' alanine repeat of 12 alanines was screened in 342 
patients diagnosed with AD as weIl as 192 patients (384 chromosomes). A 
heterozygous deletion of seven alanines (12-5) was observed in a single patient 
that was not observed in 384 control chromosomes and was confirmed by 
sequencmg and acrylamide gel electrophoresis. This deletion was paternally 
transmitted to an affected male child from a family with no history of AD. 
Interestingly, this affected male had a twin that died at 33 weeks in utero. 
Considering that this was not a de nova mutation, and was inherited from an 
unaffected father with no family history, the same three scenarios apply: 1) the 
mutation is not related to the phenotype, or does not act dominantly to pro duce 
any phenotype 2) the father is somatically mosaic for the mutation, or the 
mutation occurred in the father's mother and the gene is maternally imprinted 3) 
this rare variant requires other genetic or non-genetic factors that were not present 
during the father' s development to pro duce the phenotype. This deletion is large 
and therefore would likely produce a functional effect on the protein, therefore the 
possibility of paternal somatic mosaicism should be investigated further, as weIl 
Il 
1 li 
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as a screemng of more controls. It should be mentioned that the control 
populations contained three variants in this tract that were not observed in any 
patients diagnosed with AD: in two controls a heterozygous expansion of two 
alanines was observed (12-14) as weIl as a heterozygous deletion of one alanine 
(12-11). However, these control variants were much smaller and would 
presumably have less functional impact on the protein. 
The C-terminal or 3'alanine tract of POU3F3 (BRN-l) is larger, 
containing 16 alanines, and was screened in 342 patients with AD and 192 
controls (384 chromosomes). A heterozygous deletion of two alanines (16-14) 
was observed in one patient that was not observed in 384 control chromosomes. 
This deletion was once again paternaIly inherited in a French Canadian family, 
confirmed by sequencing as well as acrylamide gel electrophoresis. Deletions of a 
single alanine repeat have been shown to produce phenotypic results, therefore the 
smaller size of this deletion does not necessarily imply that it is not functional or 
causal. Nevertheless, a more extensive screening of controls is required before a 
decision on functional tests can be made. 
A heterozygous 21 bp deletion of seven alanines was observed (11-4 
alanines) in ARID 1 A (alternative name SMARCF 1) located at 1 p36.11. This gene 
encodes a member of the SWIISNF family which is thought to regulate 
transcription of specifie genes by altering chromatin structure in a broad range of 
tissues 151. ARID 1 A has been distinctly shown to have tumour suppressor activity 
by inhibiting gene expression, which leads to cell cycle arrestI52-154. However, this 
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gene has never been implicated in inherited forms of human genetic disease. The 
deletion was observed in 1/192 patients that was not observed in 192 controls and 
was patemally inherited from an unaffected father with no family history of AD. 
With the exception of this deletion, perfect conservation was observed in the 
remaining cases and controls. Although this is a large, rare deletion, both parents 
are of African descent for which a matching control population was not available 
at the time of the initial screening. There fore , further screening of appropriate 
population matched controls is required before a functional examination of this 
mutation is warranted. Although outside the scope of this study, given the clearly 
defined role of this protein in tumour suppression, it may be interesting to 
investigate the patemal ancestry for a history of inherited forms of cancer, and 
potentially examine the effect of this mutation on cell cycle arrest. 
The N -tenninal alanine repeat of FOXD3 located at 1 p31 contains Il 
alanine repeat~. This gene belongs to the forkhead family of transcription factors 
involved in transcriptional repression as well as activation. FOXD3 is thought to 
promote the specification of the neural crest by inducing the development of 
neural crest cells from neural tube progenitors l55 . This gene was screened in 384 
patients revealing a 12bp, 4 alanine expansion (11-15) in one patient diagnosed 
with AD with a very diverse familial background that was not observed in 192 
controls. Further screening of cases and controls is required to provide enough 
support to proceed with a functional study on this gene. 
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5.6 Conclusion 
This study was designed to determine whether alanine repeat variants may 
be worth y of an in depth examination and screening for a contributing role to the 
AD phenotype. Severa] rare variants were identified, which may contribute to the 
AD phenotype and are candidates for functional studies of these variants. The 
genes selected for study in this group represent a subset of potential genes that 
could have been chosen. Further screening of additional genes with alanine 
i: 
repeats may be performed depending on whether sorne of the rare variants can be 
successfully validated. 
Furthermore, this study identified an important class of functional coding 
variation in the human genome. Homogenizing the sampI es on different bases, 
besides those diagnosed with AD and controls, may identify certain variants 
which segregate with different phenotypes, even if they are neutra] morphological 
features. 
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Afterword 
The questions that most individuals are concerned with regarding autism 
did not find a suitable section within the body of this thesis. 1 will therefore 
address them here. These questions generally include the number of genes that 
may be involved in the phenotype, the environmental component, the increasing 
prevalence of autism, as weIl as future research and a potential cure for the 
disorder. After studying autism for a brief period during my M.Sc. research, 1 am 
left with sorne opinions on these questions. In my humble opinion, with an 
attempt at eliminating as much bias as possible, 1 believe that pure AD is a 
disorder with an almost exclusive genetic basis. 1 believe that highly penetrant de 
nova mutations, sorne of which are transmitted through a few generations in 
asymptomatic carriers, in as many as 200 and as few as 30 genes, as weIl as a 
multitude of de nova chromosomal translocations, duplications, deletions and 
inversions (sorne ofwhich have yet to occur in nature), can alllead to a phenotype 
that psychologists currently diagnose as autistic. 
1 believe that research is proceeding rapidly enough at this point that 
whole genome sequencing and techniques involving high resolution analysis of 
copy number variation will soon be financially plausible. These techniques will 
initially be used as for diagnostic testing and will eventually be used during 
standard birth examinations. Research across many disciplines will unfold such a 
substantial amount of information regarding aIl proteomic interactions, regulation, 
and effects of interacting genetic variants that, coupled with the ongoing 
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advancement in computing technology, will lead to a highly accurate diagnosis. 
This diagnosis will not have to be based on precedence; it will be able to identify 
the developmental difficulties a child will face based on predictive algorithms 
regardless of whether a particular new mutation has been previously catalogued, 
and will account for other variants present within the individual's genome. This 
diagnosis will be more aptly classified based on the molecular pathology, rather 
than the psychological pathology which will lead to discontinued use of the term 
, , 
, , autism, pervasive developmental disorder not otherwise specified, and Asperger's 
syndrome. J believe these psychological terms will eventually be considered 
interesting solely from the perspective of medical history, as a reflection of how 
far things had come by the year 2107. 
After research has led to such a profound understanding of systems at the 
molecular level, in sorne instances, it may become straightforward to use 
engineered proteins, or gene therapy as a means to assist the molecular 
1 
1 !! developmental course of a child diagnosed with AD, based on an assessment of 
, " 
1 Il 
the particular molecular pathology in question. At one point in time, 1 believed 
that a molecular intervention (gene therapy, engineered proteins) would not be 
effective at curbing symptoms of AD if it were not administered before the age of 
onset, as the nervous system would have already failed to properly develop and 
missed several essential temporal developmental checkpoints that can not be 
replicated. However, 1 have reconsidered this position, given research showing 
that rats with mutations in 111ECP2 have a phenotypic reversai when initiating the 
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expreSSIOn of functional MECP2 156, as weIl as the difficulty in identifying 
physical abnormalities ln the brains of autistic patients. Ultimately though, 1 
believe the suceess of a molecular treatment will be dependent on the type of 
mutation (toxie gain of function, dominant negative) as weIl as the function of the 
gene or protein in question, as highly specific temporal and spatial concentrations 
of a protein may be required and difficult to replicate. 
, 1 With regards to the increasing prevalence, 1 believe that the current level 
of awareness of autism in the community is based on consciousness raising and 
the shifting of arbitrary boundaries in c1inical diagnoses. Although 1 do believe 
that higher levels of environmental mutagens in a local area may increase the 
local mutation rate, l believe that this increase could only go as far as to explain 
0.1 % or less of the total increase of the prevalence of AD. 1 am often struek by 
individuals that are skeptical of shifting diagnostic trends as an explanation for the 
increasing prevalence for AD, yet are quick to describe any variant psychological 
feature in children as "autistic" that would have clearly been given a different 
label ten years ago, from attention deficits, to shy behaviour. Another interesting 
note is the common belief among those that are willing to accept wavering 
diagnostic criteria for the recent surge in public interest in AD. They will attribute 
an improvement in diagnostic criteria for the increased prevalence. However, if 
child psychology has remained historically constant, while the behavioural 
categories that we arbitrarily assign shift within our cultural environment, it 
becomes a philosophical question as to whether the change was an improvement. 
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My belief is that the tendeney to label the diagnostic criteria as an improvement is 
based on a myth of progress, assuming that ail change must be better than the 
previous system. In the specifie question of diagnosing AD, it puzzles me how a 
shifting diagnosis that increases heterogeneity, decreasing the ability to identify 
genes, delaying any cure, as weil as creating an unfounded public hysteria could 
be viewed as an "improvement". 
1 have to re-iterate that 1 am far from an expert, and these thoughts are 
merely an interesting and amusing way of concluding a thesis written on a topic 
over which 1 have spent many hours deliberating. Should my beHefs turn out to be 
false, 1 will be equally excited to witness the actual unfolding of the true answers 
to these puzzling questions that surround this mysterious disorder. 
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